Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
25.87
+0.05 (0.19%)
At close: Jan 23, 2026, 4:00 PM EST
25.75
-0.12 (-0.46%)
After-hours: Jan 23, 2026, 6:53 PM EST
Immunome Employees
Immunome had 168 employees as of September 30, 2025. The number of employees increased by 63 or 60.00% compared to the same quarter last year.
Employees
168
Change
63
Growth
60.00%
Revenue / Employee
$57,613
Profits / Employee
-$1,325,851
Market Cap
2.85B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 168 | 63 | 60.00% |
| Jun 30, 2025 | 155 | 77 | 98.72% |
| Mar 31, 2025 | 131 | 69 | 111.29% |
| Dec 31, 2024 | 118 | 63 | 114.55% |
| Sep 30, 2024 | 105 | 50 | 90.91% |
| Jun 30, 2024 | 78 | - | - |
| Mar 31, 2024 | 62 | 25 | 67.57% |
| Dec 31, 2023 | 55 | 18 | 48.65% |
| Dec 31, 2022 | 37 | -2 | -5.13% |
| Dec 31, 2021 | 39 | 16 | 69.57% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Apellis Pharmaceuticals | 710 |
| Arcus Biosciences | 627 |
| Adaptive Biotechnologies | 619 |
| Tarsus Pharmaceuticals | 323 |
| Dyne Therapeutics | 240 |
| Alumis | 223 |
| Catalyst Pharmaceuticals | 181 |
| Disc Medicine | 142 |
IMNM News
- 17 days ago - Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 19 days ago - Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 5 weeks ago - Immunome: Maintaining "Strong Buy" On Successful RINGSIDE Trial With Varegacestat - Seeking Alpha
- 5 weeks ago - Immunome Announces Pricing of Public Offering of Common Stock - Business Wire
- 5 weeks ago - Immunome Announces Proposed Public Offering of Common Stock - Business Wire
- 5 weeks ago - Immunome's experimental drug meets main goal in late-stage study - Reuters
- 5 weeks ago - Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors - Business Wire
- 6 weeks ago - Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors - Business Wire